Point Biopharma Global

POINT Biopharma Global, Inc. is a precision oncology company, which engages in the development and commercialization of radiopharmaceuticals for the treatment of cancer. It offers CanSEEK, a technology which aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

Eli Lilly

Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.

Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion

Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based cancer treatment company for about $1.4 billion. The purchase price amounts to an 87% premium to Point Biopharma's closing price on Monday.

Point Biopharma Global's stock jumps more than 80% after Lilly merger deal

INDIANAPOLIS , Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact to healthy tissue.

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024 Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212 INDIANAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. “This quarter, we began to reveal our strategy to realize one of the great opportunities presented by radioligands – the use of patient imaging to evaluate how candidate ligands perform in humans before committing substantial time and resources required to run an interventional trial,” said Joe McCann, Ph.D.

POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

POINT Biopharma is a leader in radioligand therapy, specializing in the development and commercialization of targeted radioligand therapies for cancer treatment. The company reported a strong financial standing with $519.2 million in cash and investments, enough to support operations until 2026. POINT's pipeline includes late-stage and early-stage programs targeting prostate cancer, neuroendocrine tumors, and various tumor types, with promising preliminary data and collaborations with reputable organizations.

POINT Biopharma: Leading The Future Of Radioligand Therapy

POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as this year. Positive results from the Phase 2 study of PNT2002 provide optimism for successful results in the Phase 3 SPLASH trial. I see plenty of potential stock price appreciation upon possible positive Phase 3 results and FDA approvals.

POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ: PNT) (“POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the expansion of their global supply agreements signed in 2020. The expanded agreement broadens the supply of ITM's non-carrier-added lutetium-177 (n.c.a. 177Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT's development pipeline. Financial details of the agreement were not disclosed.

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

POINT's vertically integrated platform together with AdvanCell's lead-212 (²¹²Pb) generator technology enables both the development and scaled commercialization of ²¹²Pb-labeled radioligand therapies POINT's vertically integrated platform together with AdvanCell's lead-212 (²¹²Pb) generator technology enables both the development and scaled commercialization of ²¹²Pb-labeled radioligand therapies

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

Auger electron and beta emitting isotope terbium-161 was paired with POINT's FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555

POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress

Register online today at:  https://hub.pointbiopharma.com/investor-day-june-2023

POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023

PNT2004 program's phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25 th Poster to be available starting at 9:00 AM ET, June 3 rd INDIANAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced an upcoming poster presentation for the Company's ongoing phase 1, pan-cancer, fibroblast activation protein-α (FAP-α)-targeted trial, FRONTIER (NCT05432193), at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago, IL. The Trial-in-Progress poster will include trial background information, study design considerations, and a cohort enrollment status update.

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma industry. POINT Biopharma recently received FDA Fast Track designation for their advanced 177Lu-PNT2002 therapy, which aims to treat metastatic castration-resistant prostate cancer and fill an unmet medical need.

POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials

Point Biopharma Global released first-quarter earnings. The company said that its lead therapy had received fast-track designation from the FDA.

Why Shares of Point Biopharma Global Rose Monday

POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp. POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer

U.S. FDA granted Fast Track designation for 177 Lu-PNT2002 for the treatment of mCRPC in April 2023

POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

OmniAb Inc

Verrica Pharmaceuticals Inc

Adicet Bio, Inc.

AC Immune

Altimmune

CorMedix

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and POINT Biopharma Global, Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC). Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs. PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added 177Lu.

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

AbCellera Biologics

Chimerix

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus.

Point Biopharma: Interesting, Novel Radiotherapy Developer

INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor conferences:

POINT Biopharma to Participate in Upcoming Investor Conferences

Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance

POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial

INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH).

POINT Biopharma Announces Closing of Agreements with Lantheus Holdings

Combining 177 Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model

News for Point Biopharma Global Stock (PNT)